Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.

GSK’s partnership with Theravance has yielded a pair of promising COPD treatments -- but will they be enough to protect it from Advair’s patent expirations? GSK's COPD drug candidate, Anoro Ellipta, ...

The U.S. Food and Drug Administration have approved GlaxoSmithKline’s Anoro™ Ellipta™, the company announced. The product is used to treat chronic obstructive ...

A new inhaled drug to treat a serious lung condition called chronic obstructive pulmonary disease (COPD) has been approved by the U.S. Food and Drug Administration. GlaxoSmithKline's Anoro Ellipta is ...

An FDA panel gives a big thumbs-up for Theravance's Anoro Ellipta. Trading of biopharmaceutical company Theravance (NASDAQ: THRX) was halted on Tuesday. A major decision hung in the balance as the U.S ...

Glaxo is counting on Anoro to star in its respiratory lineup, with analysts pegging peak sales at $1.4 billion; Bloomberg estimates say the drug could generate $1.2 billion in 2016. The Anoro approval ...

A new respiratory drug from GlaxoSmithKline (NYSE:GSK) and drug partner Theravance (NASDAQ:THRX) has won the backing of an advisory panel to the Food and Drug Administration. The panel on Tuesday ...

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by GlaxoSmithKline and Theravance for treating chronic obstructive pulmonary disease, the agency said Wednesday. The ...

With aging top dog Advair losing ground to generic and branded competitors alike, GlaxoSmithKline ($GSK) is grooming a lineup of respiratory up-and-comers to step in ...

Anoro Ellipta generic Anoro Ellipta is available only as a brand-name medication. It’s not currently available in generic form. A generic drug is an exact copy of the active ingredient in a brand-name ...

Umeclidinium 62.5mcg, vilanterol 25mcg; per ­inhalation; dry pwd for oral inhalation. LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in ...